164 related articles for article (PubMed ID: 10379729)
1. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.
Scherr DS; Vaughan ED; Wei J; Chung M; Felsen D; Allbright R; Knudsen BS
J Urol; 1999 Jul; 162(1):12-6; discussion 16-7. PubMed ID: 10379729
[TBL] [Abstract][Full Text] [Related]
2. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.
Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Moul JW
J Urol; 1996 Oct; 156(4):1511-6. PubMed ID: 8808919
[TBL] [Abstract][Full Text] [Related]
4. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
5. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
[TBL] [Abstract][Full Text] [Related]
6. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
[TBL] [Abstract][Full Text] [Related]
7. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
9. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors.
D'Amico AV; Schultz D; Schneider L; Hurwitz M; Kantoff PW; Richie JP
J Urol; 2000 Jun; 163(6):1797-801. PubMed ID: 10799185
[TBL] [Abstract][Full Text] [Related]
10. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
11. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
Rigaud J; Tiguert R; Decobert M; Hovington H; Latulippe E; Laverdiere J; Larue H; Lacombe L; Fradet Y
Prostate; 2004 Feb; 58(3):269-76. PubMed ID: 14743466
[TBL] [Abstract][Full Text] [Related]
12. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
[TBL] [Abstract][Full Text] [Related]
13. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
14. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
16. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
[TBL] [Abstract][Full Text] [Related]
17. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
18. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
Copp H; Bissonette EA; Theodorescu D
Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
[TBL] [Abstract][Full Text] [Related]
19. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
Allal AS; Waelchli L; Bründler MA
Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
